Search details
1.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med
; 389(1): 33-44, 2023 Jul 06.
Article
in English
| MEDLINE | ID: mdl-37407001
2.
Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab in Relapsed/Refractory CLL: Phase 1b BRUIN Trial.
Blood
; 2024 Jun 11.
Article
in English
| MEDLINE | ID: mdl-38861666
3.
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(9): 813-824, 2020 08 27.
Article
in English
| MEDLINE | ID: mdl-32846060
4.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet
; 397(10277): 892-901, 2021 03 06.
Article
in English
| MEDLINE | ID: mdl-33676628
5.
Loss of mitochondrial protease ClpP protects mice from diet-induced obesity and insulin resistance.
EMBO Rep
; 19(3)2018 03.
Article
in English
| MEDLINE | ID: mdl-29420235
6.
Proteomic analysis of the human cyclin-dependent kinase family reveals a novel CDK5 complex involved in cell growth and migration.
Mol Cell Proteomics
; 13(11): 2986-3000, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-25096995
7.
Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
Breast Cancer Res Treat
; 150(3): 487-99, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25788226
8.
Proliferating cell nuclear antigen (PCNA)-binding protein C1orf124 is a regulator of translesion synthesis.
J Biol Chem
; 287(41): 34225-33, 2012 Oct 05.
Article
in English
| MEDLINE | ID: mdl-22902628
9.
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
J Clin Oncol
; 41(24): 3988-3997, 2023 08 20.
Article
in English
| MEDLINE | ID: mdl-37192437
10.
PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity.
EMBO Rep
; 11(6): 438-44, 2010 Jun.
Article
in English
| MEDLINE | ID: mdl-20448663
11.
Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.
Breast Cancer Res
; 13(3): R80, 2011 Aug 11.
Article
in English
| MEDLINE | ID: mdl-21834972
12.
Significance of ER-Src axis in hormonal therapy resistance.
Breast Cancer Res Treat
; 130(2): 377-85, 2011 Nov.
Article
in English
| MEDLINE | ID: mdl-21184269
13.
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.
Onco Targets Ther
; 14: 3037-3049, 2021.
Article
in English
| MEDLINE | ID: mdl-33994796
14.
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Clin Cancer Res
; 27(1): 34-42, 2021 01 01.
Article
in English
| MEDLINE | ID: mdl-33082208
15.
PELP1 promotes glioblastoma progression by enhancing Wnt/ß-catenin signaling.
Neurooncol Adv
; 1(1): vdz042, 2019.
Article
in English
| MEDLINE | ID: mdl-32309805
16.
Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Oncotarget
; 8(30): 50002-50014, 2017 Jul 25.
Article
in English
| MEDLINE | ID: mdl-28654894
17.
Down-regulation of the mitochondrial matrix peptidase ClpP in muscle cells causes mitochondrial dysfunction and decreases cell proliferation.
Free Radic Biol Med
; 91: 281-92, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26721594
18.
Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis.
Cancer Res
; 75(9): 1846-58, 2015 May 01.
Article
in English
| MEDLINE | ID: mdl-25877877
19.
KDM1 is a novel therapeutic target for the treatment of gliomas.
Oncotarget
; 4(1): 18-28, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-23248157
20.
Therapeutic significance of estrogen receptor ß agonists in gliomas.
Mol Cancer Ther
; 11(5): 1174-82, 2012 May.
Article
in English
| MEDLINE | ID: mdl-22442308